Key Takeaways
- Samsung Bioepis has launched Opuviz, a biosimilar referencing Eylea (aflibercept), across Europe
- Opuviz becomes Samsung Bioepis’ fifth directly commercialized biosimilar in Europe
- The launch follows a January 2026 settlement and license agreement with Regeneron and Bayer
Samsung Bioepis announced today European launch of Opuviz (aflibercept) 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea (aflibercept).
The launch is effective today across Europe and represents Samsung Bioepis’ fifth biosimilar product to be directly commercialized by the company. Opuviz joins a growing portfolio of biosimilars that Samsung Bioepis has brought directly to the European market, including Byooviz (ranibizumab) 10 mg/mL solution for injection in a vial and Xbryk (denosumab) 120 mg solution for injection in a vial, which was launched in January.
“We are pleased to launch Opuviz in Europe, marking a significant milestone in expanding patient access to ophthalmology treatments,” said Antonio Rito, Vice President and Head of Europe at Samsung Bioepis. “Leveraging our direct commercialization capabilities, we will work closely with healthcare professionals and payers to facilitate access to this important medicine, so that patients can benefit from quality-assured, safe and effective biosimilar alternatives.”
The launch follows a settlement and license agreement announced in January 2026 between Samsung Bioepis, Regeneron, and Bayer concerning the commercialization of Samsung Bioepis’ biosimilar to Eylea 2 mg (aflibercept 40 mg/mL solution) in Europe and the rest of the world.
Beyond Europe, Samsung Bioepis’ aflibercept biosimilar is also available in the Republic of Korea under the brand name Afilivu.
